Full Press Release Details
Immunovant to Participate in Roivant R D Day 2021
NEW YORK, Sept. 27, 2021 - Immunovant, Inc. (Nasdaq IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat during Roivant R D Day 2021 on Tuesday, September 28, 2021 at 4 00 p.m. ET.
A live webcast of the event can be accessed at www.tinyurl.com roivant. A replay of the event will be archived under the Events' section on the Investors page at www.immunovant.com for 30 days following the presentation.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Director, Investor Relations Strategy